๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
NCT05754853Advanced or Metastatic Urothelium Cancer
DrugsMRG002·Pemetrexed Disodium·Gemcitabine Hydrochloride·Paclitaxel
Shanghai Miracogen Inc.
Phase 3
290
Beijing
2023-04-06
Active, closed
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
NCT05126719Recurrent or Metastatic Nasopharyngeal Carcinoma
Lepu Biopharma Co., Ltd.
Phase 2
238
Beijing, Chongqing, Fuzhou, Guangzhou, Maoming, Shantou, Shaoguan, Zhongshan
2023-04-06
Recruiting
A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
NCT05636215Locally Advanced Unresectable or Metastatic Solid Tumors
DrugIBI354
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2
368
Beijing, Chongqing
2023-04-04
Recruiting
REmimazolam vs Propofol Total Intravenous Anesthesia on Outcomes After Major Noncardiac SurgEry
NCT05728775Anesthesia, Surgery-Complications
Nanfang Hospital, Southern Medical University
Phase 4
7,188
Hefei, Huainan, Suzhou, Beijing, Chongqing, Foshan, Guangzhou, Zhongshan
2023-04-03
Active, closed
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
NCT05794906Biochemically Recurrent Prostate Cancer
DrugDarolutamide
Bayer
Phase 3
985
Beijing, Wuhan, Changsha, Nanjing, Shanghai, Chengdu, Tianjin, Hangzhou
2023-04-03
Active, closed
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
NCT05769777Dermatitis Atopic
DrugAmlitelimab
Sanofi
Phase 2
999
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jingzhou
2023-04-03
Active, closed
CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors
NCT05631899Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V, KRAS G12C
DrugsAbraxane·Cyclophosphamide
Chinese PLA General Hospital
Phase 1
9
Beijing
2023-04-03
Recruiting
Lenalidomide in the Treatment of Mucosal Behรงet's Syndrome
NCT05449548Oral Ulcer
Peking Union Medical College Hospital
Not applicable
42
Beijing
2023-04-01
Recruiting
Progesterone Therapeutic Regimen Plus Statins in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia
NCT06102863Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I
Peking University People's Hospital
Phase 2
38
Beijing
2023-04-01
Not yet open
A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone
NCT05813665Giant Cell Tumor of Bone
DrugDenosumab
Shanghai JMT-Bio Inc.
Phase 3
146
Beijing
2023-04
Not yet open
A Study of KM602 in Patients With Advanced Solid Tumors
NCT05766527Advanced Solid Tumor
Xuanzhu Biopharmaceutical Co., Ltd.
Phase 1
38
Beijing
2023-04
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Anastrozole·Exemestane
AstraZeneca
Phase 3
4,300
Baoding, Beijing, Changchun, Changsha, Chengdu, Chifeng, Dalian, Foshan
2023-03-31
By invitation
HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2
NCT05787418COVID-19
Huahui Health
Phase 3
1,200
Beijing, Shanghai
2023-03-31
Active, closed
Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
NCT05780567Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
1,946
Beijing, Guangzhou, Suining
2023-03-30
Recruiting
Al18F-NOTA-LM3 PET/CT in Patients With TIO
NCT07366099Tumor-Induced Osteomalacia
DrugsDiagnostic Test: 68Ga-DOTATATE·Diagnostic Test: Al18F-NOTA-LM3
Peking Union Medical College Hospital
Not applicable
40
Beijing
2023-03-30
Active, closed
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515Relapsed or Refractory Multiple Myeloma
DrugsTeclistamab·Carfilzomib·Bortezomib·Pomalidomide
Janssen Research & Development, LLC
Phase 3
614
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2023-03-29
Recruiting
SHengXIaN-QuYu DEcoction in Heart Failure With Reduced and Mildly Reduced Ejection Fraction
NCT05583773Heart Failure
China-Japan Friendship Hospital
Phase 4
336
Beijing, Baoding, Qinhuangdao, Gongyi, Yangzhou, Jining, Qingdao, Changzhi
2023-03-29
Active, closed
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
NCT05627557Childhood Idiopathic Nephrotic Syndrome
DrugsAcetaminophen/Paracetamol·Diphenhydramine hydrochloride·Methylprednisolone·Obinutuzumab
Hoffmann-La Roche
Phase 3
85
Beijing, Guangzhou, Hangzhou, Wuhan, Xi'an, Zhengzhou
2023-03-29
Recruiting
Total Neoadjuvant Treatment ยฑImmunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi)
NCT06229041Rectal Cancer
Peking University Cancer Hospital & Institute
Phase 3
472
Beijing
2023-03-29
Recruiting
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
NCT06041776Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy
Betta Pharmaceuticals Co., Ltd.
Phase 3
570
Beijing, Nanjing, Shanghai
2023-03-28
Recruiting
Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation
NCT06050980NSCLC
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
220
Beijing, Chongqing, Fuzhou, Nanning, Harbin, Luoyang, Zhengzhou, Changsha
2023-03-27
Recruiting
A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
NCT05718895Advanced/Metastatic Solid Tumors
DrugATG-022
Antengene Biologics Limited
Phase 1
156
Beijing, Chengdu, Fuzhou, Hefei, Jinan, Lanzhou, Qingdao, Shanghai
2023-03-27
Active, closed
650nm Low-level Red-light for Myopia Control and Prevention in Children
NCT05786586Myopia
Beijing Tongren Hospital
Not applicable
572
Beijing
2023-03-26
Recruiting
LDL Cholesterol TARGETs in OLDer Patients (Ageโ‰ฅ75 Years) With ASCVD (TARGET OLD)
NCT05765370Atherosclerotic Cardiovascular Disease, Older Patients, LDL Cholesterol
China National Center for Cardiovascular Diseases
Not applicable
4,200
Beijing
2023-03-24
Recruiting
F573 for Injection for the Treatment of Liver Injury/Failure
NCT05689645Acute Liver Failure, Acute-On-Chronic Liver Failure
Beijing Continent Pharmaceutical Co, Ltd.
Phase 2
97
Beijing, Qingyuan, Shiyan, Huaihua, Pingxiang, Changchun, Binzhou, Heze
2023-03-24
Recruiting
Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors
NCT06056362Neuroendocrine Tumors
Peking Union Medical College Hospital
Phase 1/2
80
Beijing
2023-03-23
Active, closed
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guรฉrin (BCG) in Participants With BCG-naรฏve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202Bladder Cancer
DrugsTAR-200·Cetrelimab
Janssen Research & Development, LLC
Phase 3
1,135
Beijing, Changchun, Changsha, Chengdu, Chongqing, Deyang, Guangzhou, Hangzhou
2023-03-23
Active, closed
SeQuent ยฎ Please CIS for the Treatment of INtracranial Atherosclerotic Stenosis
NCT06047964Stroke, Intracranial Atherosclerotic Stenosis
B. Braun Medical International Trading Company Ltd.
Not applicable
281
Beijing, Harbin, Nanyang, Changchun, Jining, Qingdao, Shanghai, Taiyuan
2023-03-23
Recruiting
Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma
NCT05789043Acral Melanoma
DrugsApatinib·Tislelizumab
Peking University Cancer Hospital & Institute
Phase 3
140
Beijing
2023-03-21
Recruiting
A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors
NCT05749432Solid Tumor
DrugHemay181
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 1
51
Beijing
2023-03-20
Active, closed
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
NCT05624554Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsRiabni·Ruxience·Truxima·Nemtabrutinib
Merck Sharp & Dohme LLC
Phase 3
300
Beijing, Chongqing, Guangzhou, Guiyang, Haikou, Zhengzhou, Wuhan, Changsha
2023-03-16
Recruiting
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
NCT06010342Solid Tumor
Teligene US
Phase 2
60
Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2023-03-16
Active, closed
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
DrugsMirvetuximab Soravtansine·Bevacizumab
AbbVie
Phase 3
520
Bengbu, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-03-15
Active, closed
Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors
NCT05744427Advanced Solid Tumor
DrugJSKN003
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2
725
Beijing, Changsha, Fuzhou, Guangzhou, Hangzhou, Haโ€™erbin, Hefei, Jinan
2023-03-15
Recruiting
Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM)
NCT05965284ANCA-associated Vasculitis, Maintenance Therapy
DrugsAzathioprine·Telitacicept
Chinese SLE Treatment And Research Group
Phase 4
40
Beijing
2023-03-09
Recruiting
The Study of ICP-248 in Patients With Mature B-cell Malignancies
NCT05728658Hematological Malignancies
DrugsICP-248·Orelabrutinib·Rituximab
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
191
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Zhengzhou
2023-03-09
Recruiting
OH2 Injection in Melanoma
NCT05868707Melanoma
DrugOH2
Binhui Biopharmaceutical Co., Ltd.
Phase 3
340
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang, Harbin
2023-03-08
Active, closed
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
NCT05635708Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
DrugsBGB-A445·LBL-007·Nab-paclitaxel·Pemetrexed
BeiGene
Phase 2
400
Hefei, Beijing, Fuzhou, Baoding, Harbin, Zhengzhou, Wuhan, Nantong
2023-03-07
Active, closed
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
NCT05654623Advanced Breast Cancer
DrugsARV-471·Fulvestrant
Pfizer
Phase 3
624
Hefei, Beijing, Fuzhou Fujian, Foshan, Guangzhou, Nanning, Harbin, Luoyang
2023-03-03
Recruiting
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
NCT05668403Primary Membranous Nephropathy
DrugB007
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 1
52
Zhengzhou, Shijiazhuang, Hangzhou, Beijing, Shanghai
2023-03-02
Recruiting
A Study of AK129 in Patients With Advanced Malignant Tumors
NCT05645276Advanced Malignant Tumors(Stage IA-IB)
Akeso
Phase 1
182
Beijing
2023-03-02
Recruiting
A Clinical Study of Fundus OCTA for the Identification of CMD
NCT05743140Coronary Microvascular Disease
Peking University First Hospital
Observational
400
Beijing
2023-03-01
Recruiting
Exploring the Predictive Value of Electroencephalography Features in Perioperative Neurocognitive Disorders Following Cardiovascular Surgery
NCT06692309Cardiovascular Surgery, Perioperative Neurocognitive Disorders
Beijing Chao Yang Hospital
Observational
100
Beijing
2023-03-01
Recruiting
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
NCT06410651Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
53
Beijing
2023-03-01
Recruiting
First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors or Relapse/Refractory Lymphoma
NCT05607498Advanced/Metastatic Solid Tumors, Relapse/Refractory Lymphoma
EpimAb Biotherapeutics (Suzhou)Co., Ltd.
Phase 1
150
Changsha, Baoding, Beijing, Bengbu, Guangzhou, Harbin, Shandong, Tianjin
2023-03-01
Recruiting
CART-PSMA Cells for Advanced Prostate Cancer
NCT05656573Prostate Cancer
Nova Therapeutics LLC
Phase 1
20
Beijing
2023-03-01
Recruiting
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
NCT06429839Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
55
Beijing
2023-03-01
Not yet open
Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II
NCT05764356Novel Oral Anticoagulants, NOACs, Rivaroxaban, Apixaban
Peking University First Hospital
Observational
2,000
Hefei, Beijing, Chongqing, Zhengzhou, Shanghai
2023-03
Recruiting
Development and Validation of a Real-time Prediction Model for Acute Kidney Injury in Hospitalized Patients
NCT06597838Prediction Model
Peking University First Hospital
Observational
161,876
Beijing
2023-02-28
Recruiting
Exploring the Predicting Biomarkers From Mild Cognitive Impairment to Dementia (EBMID)
NCT05697588Biomarkers, MCI Conversion to Dementia
Cuibai Wei๏ผŒClinical Professor
Observational
900
Beijing
2023-02-28
Active, closed
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
NCT05652894Metastatic Colorectal Cancer
Taizhou Hanzhong biomedical co. LTD
Phase 3
190
Bengbu, Fuyang, Hefei, Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou
2023-02-28
Recruiting
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients
NCT05824169Spinal Muscular Atrophy
GeneCradle Inc
Phase 1/2
18
Beijing, Shenyang, Suzhou
2023-02-25
Recruiting
IFNฮฑ Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors
NCT05699811Locally Advanced or Metastatic Solid Tumors
DrugsAbraxane·Nab-paclitaxel·Cyclophosphamide·Tislelizumab
Chinese PLA General Hospital
Phase 1/2
40
Beijing
2023-02-23
Recruiting
A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
NCT05800977Relapsed/Refractory Large B-Cell Lymphoma
Shanghai AbelZeta Ltd.
Phase 1/2
112
Beijing, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Shanghai
2023-02-22
Active, closed
ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.
NCT05632939Gastric Cancer, Gastroesophageal Cancer (GC)
DrugsASKB589·Capox
AskGene Pharma, Inc.
Phase 1/2
62
Beijing
2023-02-21
Active, closed
A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma
NCT05716087Mantle Cell Lymphoma (MCL)
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2
62
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Meizhou
2023-02-21
Recruiting
Observational Cohort Study of Chronic Viral Infection in the Central Nervous System
NCT07512518Progressive Multifocal Leukoencephalopathy, Immune Checkpoint Inhibitors
Peking Union Medical College Hospital
Observational
66
Beijing
2023-02-20
Recruiting
ACOART AVF RENEW: A Post Market Clinical Study
NCT06205576Stenosis of Native Hemodialysis Arteriovenous Fistulas
Acotec Scientific Co., Ltd
Not applicable
164
Beijing
2023-02-20
Recruiting
Beijing Disability Risk and Ageing Monitoring Study
NCT06394817Age Problem, Disability, Death
Xuanwu Hospital, Beijing
Observational
2,000
Beijing
2023-02-20
Active, closed
Safety and Efficacy of ZVS101e in Patients With Bietti 's Crystalline Dystrophy
NCT05832684Bietti's Crystalline Dystrophy
DrugZVS101e
Chigenovo Co., Ltd
Phase 1/2
24
Beijing, Chengdu, Tianjin
2023-02-20
Recruiting
Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
NCT05749822Primary Biliary Cholangitis
Xijing Hospital of Digestive Diseases
Phase 2/3
104
Beijing, Guangzhou, Zhengzhou, Changsha, Nanjing, Shenyang, Xi'an, Yanโ€™an
2023-02-17
Recruiting
Stent Implantation Versus Medical Therapy for Idiopathic IntracraniaL Hypertension (SIMPLE)
NCT05707442Idiopathic Intracranial Hypotension, Venous Sinus Stenosis
Beijing Tiantan Hospital
Phase 3
74
Beijing
2023-02-16
Active, closed
Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC
NCT05557838Hepatocellular Carcinoma
DrugsTremelimumab·Durvalumab
AstraZeneca
Phase 3
214
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan
2023-02-15
Recruiting
A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients
NCT05139719Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)
Sunshine Lake Pharma Co., Ltd.
Phase 2
110
Beijing
2023-02-15
Active, closed
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034Ischemic Stroke; Ischemic Attack, Transient
DrugMilvexian
Janssen Research & Development, LLC
Phase 3
12,523
Anyang, Baoji, Baotou, Beijing, Changchun, Changsha, Chengdu, Chenzhou
2023-02-15
Active, closed
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
NCT05722015Metastatic Non-small Cell Lung Cancer
DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Filgrastim·Taxol·Nab-paclitaxel
Merck Sharp & Dohme LLC
Phase 3
377
Hefei, Beijing, Wanzhou, Fuzhou, Guangzhou, Jiangmen, Shenzhen, Wuhan
2023-02-14
Active, closed
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
NCT05685238Haemophilia A, Haemophilia A With Inhibitors
Novo Nordisk A/S
Phase 3
451
Beijing, Guangzhou, Wuhan, Changsha, Jinan, Chengdu, Tianjin, Huzhou
2023-02-13
Active, closed
Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT05618327Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 1
104
Beijing
2023-02-13
Recruiting
Concomitant Hybrid Versus Catheter Ablation for Atrial Fibrillation With Hypertrophic Cardiomyopathy
NCT05610215Atrial Fibrillation, Cardiomyopathy, Hypertrophic, Radiofrequency Ablation
China National Center for Cardiovascular Diseases
Not applicable
66
Beijing
2023-02-11
Active, closed
A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
NCT05485753Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
DrugGNC-038
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
7
Beijing, Guangzhou, Zhengzhou
2023-02-10
Active, closed
A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
NCT05673785Lymphoma
DrugsBrentuximab Vedotin·Doxorubicin·Prednisone·Cyclophosphamide
Takeda
Phase 2
52
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei
2023-02-10
Active, closed
Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm
NCT05546866Non-small Cell Lung Cancer
DrugOsimertinib
AstraZeneca
Phase 2
51
Beijing, Chengdu, Fuzhou, Guangzhou, Kunming, Ningbo, Shijiazhuang, Suzhou
2023-02-09
Recruiting
Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
NCT05565807Relapsed or Refractory Multiple Myeloma
Zhejiang ACEA Pharmaceutical Co. Ltd.
Phase 1/2
84
Beijing, Guangzhou, Hangzhou
2023-02-09
Active, closed
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05578976Diffuse Large B-Cell Lymphoma
DrugsEpcoritamab·Vincristine·Doxorubicin·Prednisone
Genmab
Phase 3
900
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2023-02-08
Active, closed
Study of ST-1898 in Advanced Renal Cell Carcinoma
NCT06127238Advanced Renal Cell Carcinoma
DrugST-1898
Beijing Scitech-Mq Pharmaceuticals Limited
Phase 1/2
90
Beijing
2023-02-07
Active, closed
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) โ‰ฅ50% (MK-3475-D46)
NCT05609968Carcinoma, Non-Small-Cell Lung
DrugsSacituzumab Govitecan·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
614
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2023-02-06
Recruiting
Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
NCT05672121Age-Related Macular Degeneration
DrugKH631
Chengdu Origen Biotechnology Co., Ltd.
Phase 1/2
42
Beijing
2023-02-06
Recruiting
Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors
NCT05579275Malignant Solid Tumors
Peking University Cancer Hospital & Institute
Phase EARLY_PHASE1
24
Beijing
2023-02-06
Recruiting
Perioperative Immunonutrition Intervention and Oral Decontamination in Elderly Surgical Patients
NCT05679661Postoperative Complications
Huang YuGuang
Not applicable
590
Beijing
2023-02-06
Recruiting
Effects of COPD Standardized Management on COPD Exacerbation
NCT04664491Chronic Obstructive Pulmonary Disease
China-Japan Friendship Hospital
Not applicable
3,456
Beijing
2023-02-04
Recruiting
Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia
NCT05621070Primary Hypercholesterolaemia and Mixed Dyslipidemia
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
582
Beijing
2023-02-03
Recruiting
Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer
NCT05601505Locally Advanced Rectal Carcinoma, Circulating Tumor DNA
Peking Union Medical College Hospital
Phase 2
470
Beijing
2023-02-03
Active, closed
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
NCT05653349Primary Immune Thrombocytopenia (ITP)
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
226
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Luoyang, Zhengzhou, Changzhou, Nanchang
2023-02-03
Active, closed
Online Adaptive Radiotherapy Cervical Cancer With Reduced Margin for Cervical Cancer
NCT05880485Uterine Cervical Neoplasm
Peking Union Medical College Hospital
Phase 1/2
30
Beijing
2023-02-02
Recruiting
Geno-radiomics Based Model for Evaluation of Immunotherapy and Targeted Therapy for Advanced Soft Tissue Sarcoma
NCT06062927Advanced Soft Tissue Sarcoma
Peking Union Medical College Hospital
Observational
60
Beijing
2023-02-02
Active, closed
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
NCT05653219Primary Immune Thrombocytopenia
DrugsEltrombopag·Ianalumab
Novartis Pharmaceuticals
Phase 3
152
Guangzhou, Wuhan, Binzhou, Hangzhou, Beijing, Jinan, Tianjin
2023-02-02
Active, closed
A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia
NCT05662319Hemophilia
DrugsAntithrombin·Clotting factor concentrates·Fitusiran
Sanofi
Phase 3
91
Beijing, Guangzhou, Jinan
2023-02-01
Recruiting
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
NCT05802407Pancreatic Cancer, Resectable Carcinoma
Peking Union Medical College Hospital
Not applicable
100
Beijing
2023-02-01
Active, closed
Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)
NCT05599789Non Small Cell Lung Cancer Metastatic
DrugPembrolizumab
Peking Union Medical College Hospital
Phase 2
47
Beijing
2023-02-01
Recruiting
Extended One-level Interbody Fusion for Adjacent Vacuum Phenomenon in Lumbar Degenerative Disc Disease
NCT06029764Adjacent Segment Degeneration
Xuanwu Hospital, Beijing
Not applicable
126
Beijing
2023-02-01
Recruiting
Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa
NCT05874310X-Linked Retinitis Pigmentosa
Frontera Therapeutics
Phase EARLY_PHASE1
18
Beijing, Shanghai
2023-02-01
Recruiting
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer
NCT05802394Pancreatic Cancer, Locally Advanced
Peking Union Medical College Hospital
Not applicable
100
Beijing
2023-02-01
Recruiting
Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3
NCT05738980Hepatocellular Carcinoma
Beijing Hospital
Not applicable
88
Beijing
2023-02-01
Recruiting
Real-world Study Optimizing Nucleotide-analogues
NCT05937178Hepatitis B, Chronic
Huashan Hospital
Observational
20,000
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Nanning, Guiyang
2023-01-31
Active, closed
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
NCT05609370Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
DrugsFluoropyrimidine·Bevacizumab biosimilar·Bevacizumab·Tislelizumab
BeiGene
Phase 1/2
113
Hefei, Beijing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Shantou, Zhengzhou
2023-01-29
Active, closed
Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC
NCT05888402Local Advanced Non-small Cell Lung Cancer
DrugTislelizumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
50
Beijing
2023-01-20
Recruiting
Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors
NCT05693844Advanced or Metastatic Solid Tumors
DrugsAlbumin-Bound Paclitaxel·Fludarabine·Cyclophosphamide
Chinese PLA General Hospital
Phase 1/2
15
Beijing
2023-01-20
Recruiting
Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients
NCT05923905Sporadic and Familial Amyotrophic Lateral Sclerosis
Peking University Third Hospital
Phase 4
64
Beijing
2023-01-18
Recruiting
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT05702229Gastric Cancer
DrugsSonesitatug vedotin·Volrustomig·Xelox·Rilvegostomig
AstraZeneca
Phase 2
163
Beijing, Hangzhou, Harbin, Hefei, Kunming, Wuhan, Yinchuan, Zhengzhou
2023-01-16
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
Abivax S.A.
Phase 3
1,116
Wuhu, Beijing, Fuzhou, Guangzhou, Luoyang, Zhengzhou, Wuhan, Shenyang
2023-01-16
Rows per page Showing 4301–4400 of 5484
Previous 42 43 44 45 46 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=44

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.